GRI Bio, Inc.
GRI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001824293
No open-market purchases or sales by GRI Bio, Inc. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $164.7K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by GRI Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for GRI Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Kelly Leanne M. | Chief Financial Officer | – | Sep 22, 2025 | 0 |
| Szekeres David Leslie | Director | – | Sep 22, 2025 | 0 |
| Rongen Roelof | Director | – | Sep 22, 2025 | 0 |
| Simpson Camilla V | Director | – | Sep 22, 2025 | 0 |
| Baker David Charles | Director | – | Sep 22, 2025 | 0 |
| Hertz Walter Marc | Chief Executive Officer | 385,510 | Sep 22, 2025 | 0 |
| Chaturvedi Vipin | Chief Scientific Officer | 172,189 | Sep 22, 2025 | 0 |
| Agro Albert | Chief Medical Officer | 172,189 | Apr 24, 2023 | 0 |
| Thorell Marella | Director | 9,506 | Dec 15, 2022 | 0 |
| Payne Joseph E | Director | – | Jun 10, 2022 | 0 |
| Ammer Richard | Director | – | Jun 10, 2022 | 0 |
| Chhabra Meenu | Director | – | Mar 9, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
No insider trades match these filters.